- Conditions
- Breast Cancer, Non-small Cell Lung Carcinoma
- Interventions
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 268
matching trials from the live ClinicalTrials.gov search.
- Conditions
- ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- JDQ443, docetaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Renton, Washington
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
- Interventions
- Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non Small Cell Lung Carcinoma
- Interventions
- TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa)
- Drug
- Lead sponsor
- Telik
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 270
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Benton, Arkansas + 174 more
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer
- Interventions
- Vandetanib, Pemetrexed
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2023
- U.S. locations
- 23
- States / cities
- Casa Grande, Arizona • Chandler, Arizona • Farmington, Connecticut + 20 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Lenvatinib, Lenvatinib matched placebo, BSC
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 11
- States / cities
- Casa Grande, Arizona • Tucson, Arizona • Gilroy, California + 8 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Rociletinib Mono-Therapy, Erlotinib Mono-Therapy
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Burbank, California • Duarte, California + 47 more
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 13
- States / cities
- Duarte, California • Newport Beach, California • Orange, California + 10 more
- Conditions
- Advanced Non-small Cell Lung Cancer, HER2 Mutation
- Interventions
- Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Newport Beach, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- Oral repotrectinib (TPX-0005)
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 49
- States / cities
- Duarte, California • Glendale, California • La Jolla, California + 36 more
- Conditions
- Lung Cancer
- Interventions
- batabulin sodium
- Drug
- Lead sponsor
- Tularik
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 2
- States / cities
- San Francisco, California • Nashville, Tennessee
- Conditions
- Non Squamous, Non-small-cell Lung Cancer
- Interventions
- Tivantinib, Placebo, Erlotinib
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,048 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 111
- States / cities
- Tucson, Arizona • Los Angeles, California • Oxnard, California + 85 more
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- LYL845
- Biological
- Lead sponsor
- Lyell Immunopharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 18
- States / cities
- Sacramento, California • Santa Monica, California • Stanford, California + 14 more
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- Pamiparib, Temozolomide
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Grand Rapids, Michigan • St Louis, Missouri • New York, New York + 4 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Reno, Nevada
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Silver Spring, Maryland • Boston, Massachusetts
- Conditions
- Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors
- Interventions
- ABBV-927, ABBV-368, ABBV-181, Carboplatin, Nab-paclitaxel
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 13
- States / cities
- Springdale, Arkansas • Santa Rosa, California • New Haven, Connecticut + 10 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Rilvegostomig, Ramucirumab, Dato-DXd
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Santa Monica, California • Santa Rosa, California • Atlanta, Georgia + 3 more
- Conditions
- HER2-expressing Cancers
- Interventions
- ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
- Interventions
- Entrectinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Sutetinib Maleate Capsule
- Drug
- Lead sponsor
- Teligene US
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 9
- States / cities
- Glendale, California • La Jolla, California • Tampa, Florida + 6 more
- Conditions
- NSCLC
- Interventions
- Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 45 more
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer
- Interventions
- Docetaxel, Vandetanib
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 27
- States / cities
- Fullerton, California • Los Angeles, California • Northridge, California + 24 more